PMID- 17152789
OWN - NLM
STAT- MEDLINE
DCOM- 20070130
LR  - 20181201
IS  - 0966-8519 (Print)
IS  - 0966-8519 (Linking)
VI  - 15
IP  - 6
DP  - 2006 Nov
TI  - Comparison of fondaparinux, low molecular-weight heparin and unfractionated 
      heparin in preventing thrombus formation on mechanical heart valves: results of 
      an in-vitro study.
PG  - 809-14
AB  - BACKGROUND AND AIM OF THE STUDY: The study aim was to investigate the efficacy of 
      three different anticoagulants in preventing thrombus formation on mechanical 
      heart valves, using an in-vitro system. METHODS: Blood samples (470 ml) were 
      taken from young and healthy male volunteers and anticoagulated with 
      unfractionated heparin (UFH; n=18), low molecular-weight heparin (LMWH; n=18) or 
      fondaparinux (n=16). Bileaflet mechanical heart valves were placed in a new 
      device--the 'Thrombosis Tester'--and exposed in a continuous circulation at a 
      rate of 80 beats per min to the anticoagulated blood samples for a total exposure 
      time of 60 min. Results for thrombus weight were skewed distributed and presented 
      as log-transformed values. RESULTS: The weight of each valve was measured before 
      and after 1 h of perfusion; subsequent mean (+/-SD) thrombus weights were 0.739 
      +/- 0.573 g for UFH, 0.789 +/- 0.099 g for LMWH, and 0.934 +/- 0.145 g for 
      fondaparinux (p = 0.397 for comparison of all groups by ANOVA). Electron 
      microscopy showed concordant results with regard to thrombus formation on heart 
      valve surfaces. CONCLUSION: Fondaparinux and LMWH were as effective as UFH in 
      preventing thrombus formation on mechanical heart valves in vitro. The 
      'Thrombosis Tester' proved to be a new, unique instrument for investigating the 
      ability of anticoagulants to prevent valve thrombosis on mechanical heart valves 
      under in-vitro conditions.
FAU - Schlitt, Axel
AU  - Schlitt A
AD  - Department of Medicine II, Department of Cardiovascular Surgery, and Transfusion 
      Center, Johannes Gutenberg University, Mainz, Germany. 
      axel.schlitt@medizin.uni-halle.de
FAU - Hamilton, Kathrin
AU  - Hamilton K
FAU - Maegdefessel, Lars
AU  - Maegdefessel L
FAU - Dahm, Manfred
AU  - Dahm M
FAU - Theis, Cathrin
AU  - Theis C
FAU - Eichler, Michael
AU  - Eichler M
FAU - Brockmann, Olaf
AU  - Brockmann O
FAU - Steinseifer, Ulrich
AU  - Steinseifer U
FAU - Hauroeder, Baerbel
AU  - Hauroeder B
FAU - Hitzler, Walter E
AU  - Hitzler WE
FAU - Rupprecht, Hans J
AU  - Rupprecht HJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Heart Valve Dis
JT  - The Journal of heart valve disease
JID - 9312096
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Polysaccharides)
RN  - 129480-74-6 (ITF 300)
RN  - 9005-49-6 (Heparin)
RN  - J177FOW5JL (Fondaparinux)
SB  - IM
MH  - Anticoagulants/administration & dosage
MH  - Blood Coagulation/*drug effects
MH  - Equipment Failure Analysis
MH  - Fondaparinux
MH  - Heart Valve Prosthesis/*adverse effects
MH  - Heparin/administration & dosage/*analogs & derivatives
MH  - Heparin, Low-Molecular-Weight/*administration & dosage
MH  - Humans
MH  - Male
MH  - Polysaccharides/*administration & dosage
MH  - Prosthesis Failure
MH  - Thrombosis/*etiology/*prevention & control
MH  - Treatment Outcome
EDAT- 2006/12/13 09:00
MHDA- 2007/01/31 09:00
CRDT- 2006/12/13 09:00
PHST- 2006/12/13 09:00 [pubmed]
PHST- 2007/01/31 09:00 [medline]
PHST- 2006/12/13 09:00 [entrez]
PST - ppublish
SO  - J Heart Valve Dis. 2006 Nov;15(6):809-14.